Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evidence for an anticomplementary factor associated with human bone marrow cells.

A P Gee, K M Bruce, T D Morris

    Journal of the National Cancer Institute
    |September 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Coupled-Cluster Calculations of Neutrinoless Double-β Decay in ^{48}Ca.

    Physical review letters·2021
    Same author

    How Robust is the N=34 Subshell Closure? First Spectroscopy of ^{52}Ar.

    Physical review letters·2019
    Same author

    Cloud Quantum Computing of an Atomic Nucleus.

    Physical review letters·2018
    Same author

    Structure of the Lightest Tin Isotopes.

    Physical review letters·2018
    Same author

    Evidence for prevalent Z = 6 magic number in neutron-rich carbon isotopes.

    Nature communications·2018
    Same author

    Manufacturing genetically modified T cells for clinical trials.

    Cancer gene therapy·2015
    Same journal

    Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE.

    Journal of the National Cancer Institute·2026
    Same journal

    Beyond R2: Assessing quality of trial level surrogate endpoints in colorectal cancer.

    Journal of the National Cancer Institute·2026
    Same journal

    A novel classification of small bowel adenocarcinoma based on the hidden genome classifier: a multi-institutional study.

    Journal of the National Cancer Institute·2026
    Same journal

    Response to Yu, Wang and Ge.

    Journal of the National Cancer Institute·2026
    Same journal

    Re: Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma.

    Journal of the National Cancer Institute·2026
    Same journal

    Welcome reduction of US cervical cancer rates despite state differences.

    Journal of the National Cancer Institute·2026
    See all related articles

    Human bone marrow cells release a factor that inhibits complement-mediated cell lysis. This soluble factor, which slows the complement cascade, could hinder antibody-based tumor cell purging for bone marrow transplants.

    Area of Science:

    • Immunology
    • Biochemistry

    Background:

    • Complement (C) system plays a crucial role in immune responses, including antibody-mediated cell lysis.
    • Bone marrow purging is a technique used in autologous transplantation to remove residual tumor cells.

    Purpose of the Study:

    • To investigate the anticomplementary activity of human bone marrow cells.
    • To identify the mechanism by which bone marrow cells inhibit complement-mediated lysis.

    Main Methods:

    • Sheep erythrocytes were sensitized with antibodies.
    • The effect of human bone marrow cells on complement-mediated lysis was assessed.
    • The anticomplementary activity was characterized by analyzing its effect on the complement cascade.

    Main Results:

    Related Experiment Videos

  • Human bone marrow cells inhibited complement-mediated lysis of antibody-sensitized erythrocytes.
  • This inhibition was due to a soluble factor released by the bone marrow cells.
  • The factor acted early in the complement cascade, accelerating the decay of C2.

    • Conclusions:

    • A soluble factor from bone marrow cells inhibits complement activity by affecting C2 decay.
    • This finding presents a challenge for using antibody and complement to purge tumor cells from bone marrow for autologous transplantation.